A probiotic strain produced by BioGaia (Raleigh, NC) has demonstrated a substantially reduced frequency of regurgitation in infants.
A probiotic strain produced by BioGaia (Raleigh, NC) has demonstrated a substantially reduced frequency of regurgitation in infants, according to research published in the European Journal of Clinical Investigation.
The probiotic specialist announced the news as supporting a previous trial on its Lactobacillus reuteri Protectis strain against uncomplicated infant regurgitation.
In the double-blind, placebo-controlled study, 42 formula-fed infants under four months of age were assigned to daily supplementation of placebo or the probiotic for 30 days. Incidence of regurgitate was reduced by 80% in the probiotic group compared to 33% in the placebo group. During the final week, regurgitation was reduced by an average 75% with probiotic compared to placebo.
“Uncomplicated regurgitation is common among infants and we are convinced that these exciting results with L. reuteri will have an impact on future handling of infants with persistent regurgitation,” said study author Flavia Indrio of the University of Bari (Italy) department of pediatrics.
Check out the study’s abtract here.
The Nutritional Outlook Podcast Episode 39: Nutritional Outlook's Ingredients to Watch in 2025
February 25th 2025In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2025.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?